Raymond T. Keane

ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA.

Wilson, Elser, Moscowitz, Edelman & Decker LLP provides legal services. It offers litigation, business and financial, insurance and reinsurance, and government relations services. The firm offers its services to the aesthetics law, automotive and motorized vehicle, aviation and aerospace, chemical, construction, energy, environmental, finance, gaming, sweepstakes and contests, healthcare, hospitality, tourism and leisure, insurance and reinsurance, manufacturing, pharmaceutical, professional services, railroad, real estate, retail, sports, technology, and transportation sectors. The company was founded by Thomas W. Wilson Sr. in 1978 and is headquartered in White Plains, NY.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Martin Clearwater & Bell LLP is a legal firm that has been providing defense trial counsel and legal advice to various clients for over a century. The private company is based in New York, NY. The company's clients include healthcare providers, corporations, privately-held companies, governmental entities, municipalities, and individuals.

Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.